SPAC30D11.14c Antibody

What is SPAC30D11.14c Antibody and what does it target?

SPAC30D11.14c Antibody (CSB-PA296442XA01SXV) is a rabbit polyclonal antibody that targets the SPAC30D11.14c protein from Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. It is an antigen-affinity purified antibody stored in 50% glycerol with 0.01M PBS (pH 7.4) and 0.03% Proclin 300 as a preservative. This antibody is specifically developed for research applications in the study of S. pombe proteins and cellular processes .

What applications is SPAC30D11.14c Antibody validated for?

The SPAC30D11.14c Antibody has been tested and validated for use in Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications. These methods allow researchers to detect and quantify the target protein in experimental samples. When using this antibody, it's critical to include proper controls to ensure accurate identification of the antigen .

How should SPAC30D11.14c Antibody be stored to maintain its efficacy?

Upon receipt, the SPAC30D11.14c Antibody should be stored at -20°C or -80°C to maintain its stability and efficacy. Researchers should avoid repeated freeze-thaw cycles as these can degrade the antibody and reduce its performance in experimental applications. Working aliquots can be prepared to minimize freeze-thaw cycles and extend the useful life of the product .

How can I validate SPAC30D11.14c Antibody for my specific experimental conditions?

Proper validation is essential for ensuring reliable results. Following the "5 pillars" consensus approach to antibody validation is recommended: (1) Genetic strategies using knockout or knockdown models, (2) Orthogonal strategies comparing antibody results with independent methods, (3) Independent antibody strategies using multiple antibodies targeting different epitopes, (4) Expression of tagged proteins, and (5) Immunocapture followed by mass spectrometry. For S. pombe research, utilizing CRISPRi libraries to knock down your target gene can be particularly useful for validation experiments .

What controls should I include when using SPAC30D11.14c Antibody in Western blot experiments?

When performing Western blot experiments with SPAC30D11.14c Antibody, include the following controls: (1) Positive control - lysate from wild-type S. pombe expressing the target protein, (2) Negative control - lysate from cells where SPAC30D11.14c is knocked down using CRISPRi technology, (3) Secondary antibody-only control to check for non-specific binding, (4) Loading control using a housekeeping protein antibody, and (5) Pre-absorbed antibody control to confirm specificity. These controls help ensure that band detection is specific to the target protein .

How can I assess batch-to-batch variability of SPAC30D11.14c Antibody?

Batch-to-batch variability is a significant concern with antibodies. To assess this variability: (1) Perform side-by-side testing of different batches using the same experimental conditions and samples, (2) Compare signal intensity, background levels, and specificity patterns, (3) Document lot numbers and performance metrics for each batch, (4) Consider creating a standard curve using recombinant SPAC30D11.14c protein to quantify detection sensitivity, and (5) Maintain a reference sample that can be used to benchmark new antibody batches. Consistent methodology is critical for meaningful comparisons .

How should I optimize antigen retrieval when using SPAC30D11.14c Antibody in fixed S. pombe samples?

Optimizing antigen retrieval for SPAC30D11.14c detection in fixed S. pombe requires systematic testing. Begin with a heat-induced epitope retrieval method using citrate buffer (pH 6.0) at 95°C for 15-20 minutes. If results are suboptimal, test alternative buffers such as EDTA (pH 8.0) or Tris-EDTA (pH 9.0). For chemical retrieval, try proteinase K digestion (10-20 μg/ml for 10-15 minutes). The cell wall of S. pombe can be particularly challenging, so consider enzymatic digestion with zymolyase (0.5-1.0 mg/ml for 30 minutes at 30°C) prior to fixation. Document successful protocols thoroughly, as retrieval conditions can significantly impact antibody performance .

What dilution series should I test when optimizing SPAC30D11.14c Antibody for Western blot analysis?

When optimizing SPAC30D11.14c Antibody dilutions for Western blot, start with a broad range: 1:500, 1:1000, 1:2000, and 1:5000. Prepare identical blots with the same amount of protein loaded in each lane and incubate with different antibody dilutions. The optimal dilution should provide a clear specific signal with minimal background. If the signal is too strong at 1:5000, extend your series to 1:10,000. Conversely, if the signal is weak at 1:500, try 1:250 or 1:100. Remember that higher antibody concentrations often increase background, so balance sensitivity and specificity. Document the optimal dilution for your specific experimental conditions and protein abundance .

How can I use SPAC30D11.14c Antibody in combination with CRISPRi techniques in S. pombe?

To effectively combine SPAC30D11.14c Antibody with CRISPRi techniques in S. pombe: (1) Establish baseline expression levels of SPAC30D11.14c protein using the antibody in wild-type cells, (2) Design appropriate guide RNAs targeting the SPAC30D11.14c gene for CRISPRi knockdown, (3) After implementing CRISPRi, use the antibody to quantify the degree of protein depletion by Western blot, (4) Correlate protein levels with phenotypic changes to understand gene function, (5) Consider using the antibody for immunofluorescence to examine changes in protein localization after partial knockdown. This combined approach allows for validation of both the antibody specificity and CRISPRi efficiency while generating functional insights .

How can I use SPAC30D11.14c Antibody for co-immunoprecipitation studies in S. pombe?

For co-immunoprecipitation (co-IP) with SPAC30D11.14c Antibody: (1) Optimize cell lysis conditions that preserve protein-protein interactions; try gentle non-ionic detergents like 0.5% NP-40 or 1% Triton X-100 in a buffer containing 150mM NaCl, 50mM Tris-HCl pH 7.5, and protease inhibitors, (2) Pre-clear lysates with Protein A/G beads to reduce non-specific binding, (3) Incubate cleared lysates with SPAC30D11.14c Antibody at 4°C overnight (typically 2-5μg antibody per 1mg protein lysate), (4) Capture antibody-protein complexes with Protein A/G beads, (5) Wash extensively with lysis buffer, (6) Elute and analyze by SDS-PAGE followed by Western blot or mass spectrometry. Validate interactions by reciprocal co-IP using antibodies against suspected interacting partners .

What methods can I use to quantify SPAC30D11.14c protein expression across different growth phases of S. pombe?

To quantify SPAC30D11.14c protein expression across S. pombe growth phases: (1) Establish synchronous cultures using methods such as nitrogen starvation and release or lactose gradient centrifugation, (2) Collect samples at defined time points (early log, mid-log, late log, and stationary phases), (3) Prepare cell lysates using standardized protocols with equal protein loading, (4) Perform quantitative Western blot using SPAC30D11.14c Antibody with appropriate loading controls (e.g., α-tubulin), (5) Consider using fluorescent secondary antibodies for more accurate quantification, (6) Analyze images using densitometry software with standard curves. For absolute quantification, include recombinant SPAC30D11.14c protein standards in your blots .

How should I interpret unexpected molecular weight bands when using SPAC30D11.14c Antibody in Western blots?

When encountering unexpected bands in Western blots: (1) Compare observed molecular weights with the predicted size of SPAC30D11.14c protein (check databases for expected size), (2) Consider post-translational modifications (phosphorylation, glycosylation, ubiquitination) that may alter migration, (3) Evaluate potential proteolytic cleavage by testing different protease inhibitor cocktails, (4) Assess sample preparation conditions that might cause protein aggregation or degradation, (5) Run a knockdown control to determine which bands are specific, (6) Perform mass spectrometry analysis of the unexpected bands to identify the proteins. Document all observations systematically to build a reliable profile of antibody performance for your specific conditions .

What strategies can resolve high background issues when using SPAC30D11.14c Antibody in immunofluorescence?

To resolve high background in immunofluorescence: (1) Optimize fixation – test both formaldehyde (2-4%) and methanol fixation to determine which preserves epitope accessibility while maintaining cellular architecture, (2) Increase blocking stringency using 5-10% normal serum from the species of the secondary antibody combined with 0.1-0.3% Triton X-100, (3) Test a titration of primary antibody concentrations (1:100 to 1:1000), (4) Extend washing steps (4-6 washes of 10 minutes each), (5) Use a highly cross-adsorbed secondary antibody at lower concentrations (1:500 to 1:2000), (6) Include an additional blocking step with unconjugated Fab fragments, (7) Consider autofluorescence quenching with 0.1% sodium borohydride or 50mM NH₄Cl treatment prior to antibody incubation .

How can I determine if contradictory results between SPAC30D11.14c Antibody signal and functional data are due to antibody limitations?

When facing contradictions between antibody results and functional data: (1) Validate antibody specificity using knockdown/knockout controls, (2) Test alternative antibody lots or sources if available, (3) Apply orthogonal detection methods such as mRNA quantification by RT-qPCR or protein tagging approaches, (4) Consider the possibility of post-translational modifications or protein isoforms affecting epitope recognition, (5) Evaluate experimental conditions that might influence protein expression or epitope accessibility, (6) Perform epitope mapping to understand what region of the protein the antibody recognizes, (7) Document all validation attempts systematically. Remember that antibody limitations are a common source of irreproducible results in scientific research, and thorough validation is essential .

What information should I include in publications to ensure reproducibility when using SPAC30D11.14c Antibody?

For reproducible research with SPAC30D11.14c Antibody, publications should include: (1) Complete antibody identification details (supplier, catalog number, lot number, RRID if available), (2) Host species, clonality, and immunogen information, (3) Detailed validation methods performed, including images of controls, (4) Specific experimental conditions (dilutions, incubation times, temperatures, buffers), (5) Sample preparation protocols, (6) Image acquisition parameters and processing methods, (7) Quantification methods with statistical analyses, (8) Any observed limitations or inconsistencies. This comprehensive reporting allows other researchers to accurately replicate your findings and builds confidence in the antibody's performance characteristics .

How can I contribute to community knowledge about SPAC30D11.14c Antibody performance?

To contribute to community knowledge: (1) Submit detailed validation data to antibody validation repositories like Antibodypedia or the Antibody Registry, (2) Share protocols on platforms like protocols.io, including successful and failed approaches, (3) Report antibody performance details in publications, even in supplementary materials if space is limited, (4) Participate in initiatives like YCharOS that systematically evaluate antibody performance, (5) Contact the supplier with detailed feedback on performance, (6) Share raw data where possible to allow others to analyze your results independently. Community-based validation efforts are essential for improving research quality and reducing waste due to poorly performing antibodies .

How can SPAC30D11.14c Antibody be used in conjunction with CRISPRi libraries for studying essential gene functions in S. pombe?

SPAC30D11.14c Antibody can be integrated with CRISPRi technologies by: (1) Using the antibody to quantify the degree of protein depletion achieved by different guide RNAs targeting SPAC30D11.14c, (2) Correlating protein levels with phenotypic outcomes to establish dose-response relationships, (3) Employing the antibody to examine protein localization changes under partial knockdown conditions via immunofluorescence, (4) Combining CRISPRi-mediated gene repression with antibody-based protein detection to study protein stability and turnover rates, (5) Using the antibody to assess compensatory mechanisms that may be activated in response to gene repression. This integrated approach provides deeper insights into gene function than either technique alone .

What experimental design considerations should I account for when studying SPAC30D11.14c protein interactions in metabolic pathway analyses?

For studying SPAC30D11.14c protein interactions in metabolic pathways: (1) Consider growth conditions that may influence metabolic states (carbon source, growth phase, stress conditions), (2) Design co-immunoprecipitation experiments with SPAC30D11.14c Antibody under native conditions that preserve weak or transient interactions, (3) Include crosslinking approaches (e.g., formaldehyde or DSP) to capture dynamic interactions, (4) Combine with proximity-labeling techniques like BioID or APEX2 to identify the protein's interactome, (5) Validate interactions through reciprocal pull-downs and functional assays, (6) Correlate interaction data with metabolomic profiling to establish functional connections. The flexibility of metabolic pathway interactions requires careful experimental design to capture physiologically relevant protein associations .